News for Novan, Inc. (0A4P.L)

Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMIâ„¢

Royalty aggregators like Royalty Pharma, Ligand, and XOMA are revolutionizing biotech by providing upfront cash for R&D. Read more on LGND stock here.

Pharmaceutical executive Scott Plesha named CEO Lead product ZELSUVMI expected to be commercially available in late 2024 ...

As the year draws to a close, it's time to assess the current status regarding the approval of novel drugs, also referred to as new molecular entities. As of this writing, 55 novel drugs have been greenlighted by the U.

Tailoring wart therapeutics to individual patients based on factors like wart type, location, and responsiveness to previous treatments can lead to more...

NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of Nymox Pharmaceutical Corporation. Nymox Pharmaceutical Corporation's securities were

Ligand Pharmaceuticals Incorporated (NASDAQ:NASDAQ:LGND) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ETCompany ParticipantsSimon Latimer - Head, Investor RelationsTodd Davis -...

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.22%

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 0.25% on Monday. The Dow traded up 0.25% to 34,596.04 while the NASDAQ rose 0.92% to 14,243.64. The S&P 500, also rose, gaining, 0.43% to 4,524.74.

– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a…

DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast…

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.

Vancouver, Kelowna, Delta, BC - May 9, 2022 (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces its we...